Get the Stockscreener App
1.25
8.70%
0.10
Okyo Pharma Limited stock is traded at $1.25, with a volume of 558.17K.
It is up +8.70% in the last 24 hours and up +20.66% over the past month.
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
See More
Previous Close:
$1.15
Open:
$1.14
24h Volume:
558.17K
Relative Volume:
4.04
Market Cap:
$39.03M
Revenue:
-
Net Income/Loss:
$-13.27M
P/E Ratio:
-7.622
EPS:
-0.164
Net Cash Flow:
$-7.70M
1W Performance:
+12.11%
1M Performance:
+20.66%
6M Performance:
+14.68%
1Y Performance:
-11.97%
1-Day Range:
$1.14
$1.27
1-Week Range:
$1.08
$1.27
52-Week Range:
$0.8075
$1.90
Okyo Pharma Limited Stock (OKYO) Company Profile
Compare OKYO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
1.25 | 39.03M | 0 | -13.27M | -7.70M | -0.164 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.24 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
695.97 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
616.76 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.50 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
268.06 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Okyo Pharma Limited Stock (OKYO) Latest News
OKYO Pharma advances neuropathic corneal pain drug trial - MSN
OKYO Pharma (NASDAQ:OKYO) Receives “Buy” Rating from HC Wainwright - Defense World
H.C. WAINWRIGHT MAINTAINS BUY RATING ON OKYO PHARMA STOCK By Investing.com - Investing.com Australia
H.C. WAINWRIGHT MAINTAINS BUY RATING ON OKYO PHARMA STOCK - Investing.com India
Contrasting OKYO Pharma (NASDAQ:OKYO) and CG Oncology (NASDAQ:CGON) - Defense World
Buy Recommendation for OKYO Pharma Driven by Promising Urcosimod Efficacy and Market Potential - TipRanks
Okyo Pharma's OK-101 renamed urcosimod for eye pain - MSN
H.C. Wainwright maintains Buy on OKYO Pharma with $7 target - MSN
OKYO Pharma’s lead asset receives USAN designation "urcosimod By Investing.com - Investing.com Nigeria
OKYO Pharma's lead asset receives USAN designation "urcosimod - MSN
OKYO Pharma has dry eyes as a lucrative prize in its sights - Proactive Investors UK
Okyo Pharma's OK-101 renamed urcosimod for eye pain By Investing.com - Investing.com South Africa
OKYO Pharma's lead asset receives USAN designation "urcosimod By Investing.com - Investing.com UK
OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod - GlobeNewswire
OKYO Pharma’s Lead Asset OK-101 Receives USAN as Urcosimod - TipRanks
Okyo Pharma Limited Announces OK-101 Officially Assigned USAN : Urcosimod -February 12, 2025 at 07:01 am EST - Marketscreener.com
Revolutionary Eye Drug Urcosimod Targets Two Major Unmet Medical Needs - StockTitan
OKYO Pharma says OK-101 gains USAN reflecting role in ocular disease modulation - Proactive Investors USA
H.C. Wainwright maintains Buy on OKYO Pharma with $7 target By Investing.com - Investing.com South Africa
OKYO Pharma (NASDAQ:OKYO) Receives Buy Rating from HC Wainwright - Defense World
Yi Chen’s Buy Recommendation on OKYO Pharma: Promising Potential of OK-101 for Neuropathic Corneal Pain Amid Financial and Regulatory Challenges - TipRanks
OKYO Pharma Announces Chairman and CEO Acquire Shares -February 03, 2025 at 09:04 am EST - Marketscreener.com
OKYO Pharma poised for multi-billion-dollar opportunity in ocular treatment market, analysts believe - Proactive Investors Australia
OKYO Pharma Announces Chairman and CEO Acquire Shares -January 31, 2025 at 07:00 am EST - Marketscreener.com
OKYO Pharma insiders buy shares amid clinical trials - MSN
OKYO Pharma insiders acquire shares - Proactive Investors USA
OKYO Pharma insiders buy shares amid clinical trials By Investing.com - Investing.com South Africa
OKYO Pharma Executives Increase Shareholdings, Affirming Market Confidence - TipRanks
OKYO Pharma Announces Chairman and CEO Acquire Shares - The Manila Times
This Biotech's Eye Pain Drug Could Transform a $6.4B Untapped Market - StockTitan
OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter - GlobeNewswire
OKYO Pharma Advances Clinical Trials with Encouraging Interim Results - TipRanks
OKYO Pharma advances neuropathic corneal pain drug trial By Investing.com - Investing.com Australia
OKYO Pharma nears full enrollment for neuropathic corneal pain trial - Proactive Investors UK
MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Okyo Pharma Limited Stock (OKYO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):